JP2020529440A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529440A5
JP2020529440A5 JP2020505905A JP2020505905A JP2020529440A5 JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5 JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020529440 A5 JP2020529440 A5 JP 2020529440A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
acceptable salt
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044973 external-priority patent/WO2019028234A1/en
Publication of JP2020529440A publication Critical patent/JP2020529440A/ja
Publication of JP2020529440A5 publication Critical patent/JP2020529440A5/ja
Pending legal-status Critical Current

Links

JP2020505905A 2017-08-04 2018-08-02 糖尿病および関連する状態の処置におけるガボキサドールの使用 Pending JP2020529440A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541260P 2017-08-04 2017-08-04
US62/541,260 2017-08-04
PCT/US2018/044973 WO2019028234A1 (en) 2017-08-04 2018-08-02 USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS

Publications (2)

Publication Number Publication Date
JP2020529440A JP2020529440A (ja) 2020-10-08
JP2020529440A5 true JP2020529440A5 (https=) 2021-09-09

Family

ID=65230918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505905A Pending JP2020529440A (ja) 2017-08-04 2018-08-02 糖尿病および関連する状態の処置におけるガボキサドールの使用

Country Status (10)

Country Link
US (2) US10813918B2 (https=)
EP (1) EP3648762A4 (https=)
JP (1) JP2020529440A (https=)
KR (1) KR20200047557A (https=)
CN (1) CN111201022A (https=)
AU (1) AU2018309049A1 (https=)
CA (1) CA3071939A1 (https=)
IL (1) IL272414A (https=)
MX (1) MX2020001342A (https=)
WO (1) WO2019028234A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
AU2023255685A1 (en) * 2022-04-20 2024-12-05 Aclipse Two Inc. Treatment of gastrointestinal diseases
AU2024334368A1 (en) * 2023-08-29 2026-04-02 Aclipse Two Inc. Pharmaceutical composition for use in the disease treatments

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
ZA200607427B (en) * 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
WO2006102093A1 (en) * 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
CA2843875C (en) * 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
EP3236994A1 (en) * 2014-12-23 2017-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用

Similar Documents

Publication Publication Date Title
JP2020529440A5 (https=)
JP4846063B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP6066144B2 (ja) 併用医薬
TW202202139A (zh) 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重
US20110071166A1 (en) Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine
KR20260036616A (ko) Glp1r 작용제의 치료적 용도
CN109310697A (zh) 利格列汀和二甲双胍的组合
JP2018509419A5 (https=)
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
TW202435860A (zh) 用於治療疼痛的ｒ—ｍｄｍａ
JP2021001221A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
CN1921881A (zh) 羟基化氨基酸用于治疗糖尿病的用途
JP6550160B2 (ja) 糖尿病及び関連症状の治療のための方法及び組成物
TW201210586A (en) Methods of using diacerein as an adjunctive therapy for diabetes
WO2006116470A1 (en) Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment
JPWO2007007757A1 (ja) ＰＰＡＲγアゴニストを含有する医薬組成物
JP7658909B2 (ja) 筋ジストロフィー治療薬
WO2019229643A1 (en) Combinations comprising tropifexor and cenicriviroc
WO2011002012A1 (ja) Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬
US7608625B2 (en) Method for treating bruxism and bruxism-related diseases
JP2006519881A5 (https=)
JP2009513593A (ja) 糖尿病の治療
JP2017128545A (ja) 併用医薬
TWI461192B (zh) 降低血脂異常病患之糖化血色素的醫藥組成物
WO2012133693A1 (ja) 糖尿病治療用の組合せ医薬